Proton Pump Inhibitor

## Report on Proton Pump Inhibitors Adverse Drug Reaction Labeling **1. Executive Summary:** This report analyzes a directive from the Central Drugs Standard Control Organization (CDSCO), Government of India, regarding Proton Pump Inhibitors (PPIs). The directive mandates that manufacturers of PPIs, such as Pantoprazole, Omeprazole, Lansoprazole, Esomeprazole, and Rabeprazole, incorporate "Acute Kidney Injury" as an adverse drug reaction (ADR) in the package insert/promotional literature of these drugs. This amendment stems from adverse drug reaction reports and subsequent recommendations from expert committees, aiming to improve patient safety through better-informed prescribing practices and heightened awareness of potential risks. **2. Introduction:** This report aims to provide an overview and analysis of the CDSCO directive concerning the labeling of Proton Pump Inhibitors (PPIs) to include Acute Kidney Injury (AKI) as an adverse drug reaction. The analysis is based solely on the provided policy text and focuses on understanding the directive's purpose, provisions, and potential impact. **3. Policy Overview:** This is an amendment to existing regulations governing the labeling of PPIs. * **Core Objective(s):** The core objective, inferred from the provided text, is to enhance patient safety by ensuring that healthcare professionals and patients are informed about the potential risk of Acute Kidney Injury associated with the use of PPIs. This will be achieved by mandating the inclusion of AKI as an ADR in the drug's package insert and promotional literature. **4. Background and Rationale:** This is an amendment to existing regulations regarding PPI labeling. The rationale for this specific amendment is driven by: * Reports of Adverse Drug Reactions (ADRs) related to PPIs, specifically concerning Acute Kidney Injury. * Evaluation by the National Coordination Centre for Pharmacovigilance Programme of India (NCCPvPI) and the Subject Expert Committee (SEC) who recommended including AKI as an ADR. The underlying issue is the need to communicate potential risks of commonly used medications to patients and healthcare professionals to improve prescribing practices and patient outcomes. **5. Key Provisions / Changes:** This is an amendment so we focus on changes: * **Specific Part of the Original Policy Being Changed:** The amendment changes the package insert/promotional literature of PPIs marketed in India. * **New Rule/Provision:** The new rule is that manufacturers of PPIs *must* include "Acute Kidney Injury" as an adverse drug reaction in the package insert and promotional literature of their products. * **Difference/Effect of This Change:** The effect of this change is to enhance the information provided to healthcare professionals and patients regarding the potential risks associated with PPI use. This potentially leads to more informed prescribing decisions, earlier detection of AKI, and improved patient outcomes. **6. Target Audience and Stakeholders:** The primary target audience and stakeholders include: * **Manufacturers of PPIs:** They are directly responsible for implementing the labeling changes. * **State/UT Drugs Controllers:** They are tasked with directing manufacturers to comply with the directive and reporting back to the CDSCO. * **Healthcare Professionals:** Prescribers need to be aware of this potential risk * **Patients:** The ultimate beneficiaries, who will be better informed about the risks associated with PPIs. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** * **CDSCO (Central Drugs Standard Control Organization):** Responsible for issuing the directive and overseeing its implementation. * **State/UT Drugs Controllers:** Responsible for directing manufacturers within their jurisdiction to comply. * **NCCPvPI (National Coordination Centre for Pharmacovigilance Programme of India):** Responsible for ADR monitoring and signal detection. * **SEC (Subject Expert Committee):** Responsible for providing expert recommendations. * **Timelines or Procedures:** The text does not specify exact timelines, but it requests State/UT Drugs Controllers to report back on the "action taken in this regard," implying a need for timely implementation. **8. Expected Outcomes / Impact of Changes:** The likely intended outcomes of this amendment are: * Increased awareness among healthcare professionals and patients regarding the risk of Acute Kidney Injury associated with PPIs. * More informed prescribing decisions, potentially leading to reduced incidence of PPI-related AKI. * Earlier detection and management of AKI in patients taking PPIs, potentially improving patient outcomes. * Strengthened pharmacovigilance and drug safety monitoring systems. **9. Conclusion:** The CDSCO directive mandating the inclusion of Acute Kidney Injury as an adverse drug reaction in the labeling of Proton Pump Inhibitors is a significant step towards enhancing patient safety. By ensuring that healthcare professionals and patients are adequately informed about the potential risks associated with these commonly used medications, this amendment aims to promote more informed prescribing practices and ultimately improve patient outcomes. The directive highlights the importance of ongoing pharmacovigilance and the role of regulatory bodies in responding to emerging safety concerns.

Key Entities Referenced